CN114846137A - 一种亲和填料及其制备方法和应用 - Google Patents
一种亲和填料及其制备方法和应用 Download PDFInfo
- Publication number
- CN114846137A CN114846137A CN201980103155.9A CN201980103155A CN114846137A CN 114846137 A CN114846137 A CN 114846137A CN 201980103155 A CN201980103155 A CN 201980103155A CN 114846137 A CN114846137 A CN 114846137A
- Authority
- CN
- China
- Prior art keywords
- heparanase
- solution
- sodium chloride
- affinity
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000945 filler Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 102100024025 Heparanase Human genes 0.000 claims abstract description 73
- 108010037536 heparanase Proteins 0.000 claims abstract description 73
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229920000669 heparin Polymers 0.000 claims abstract description 29
- 229960002897 heparin Drugs 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 20
- 239000011159 matrix material Substances 0.000 claims abstract description 18
- 239000003223 protective agent Substances 0.000 claims abstract description 18
- 230000005764 inhibitory process Effects 0.000 claims abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 127
- 239000000243 solution Substances 0.000 claims description 66
- 239000011780 sodium chloride Substances 0.000 claims description 63
- 229920002971 Heparan sulfate Polymers 0.000 claims description 27
- 238000010828 elution Methods 0.000 claims description 23
- 239000000758 substrate Substances 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 239000007983 Tris buffer Substances 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000000967 suction filtration Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 3
- 239000012065 filter cake Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 2
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
- 229940051593 dermatan sulfate Drugs 0.000 claims description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
- -1 dialyze Substances 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- 229940045200 cardioprotective agent Drugs 0.000 claims 3
- 239000012659 cardioprotective agent Substances 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 1
- 238000011068 loading method Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 230000008878 coupling Effects 0.000 abstract description 3
- 238000010168 coupling process Methods 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 230000009401 metastasis Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 238000000926 separation method Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 6
- 108090000054 Syndecan-2 Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108010075254 C-Peptide Proteins 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000002067 Protein Subunits Human genes 0.000 description 3
- 108010001267 Protein Subunits Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- JRMSLDWZFJZLAS-UHFFFAOYSA-M [7-(dimethylamino)-1,9-dimethylphenothiazin-3-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].CC1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC(C)=C3N=C21 JRMSLDWZFJZLAS-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
一种亲和填料及其制备方法和应用,所述亲和填料为与乙酰肝素酶结合域多肽偶联的基质,所述乙酰肝素酶结合域多肽经活性中心保护剂处理。通过在基质上偶联乙酰肝素酶结合域多肽得到亲和填料,使用该亲和填料可从肝素中分离得到更高乙酰肝素酶抑制活性的组分,该组分的抑制活性相比肝素提高约10倍,可用于抗肿瘤药物的开发,具有广阔的应用前景。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/129112 WO2021128255A1 (zh) | 2019-12-27 | 2019-12-27 | 一种亲和填料及其制备方法和应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410700176.1A Division CN118684788A (zh) | 2019-12-27 | 一种亲和填料及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114846137A true CN114846137A (zh) | 2022-08-02 |
CN114846137B CN114846137B (zh) | 2024-06-28 |
Family
ID=76573487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980103155.9A Active CN114846137B (zh) | 2019-12-27 | 2019-12-27 | 一种亲和填料及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114846137B (zh) |
WO (1) | WO2021128255A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113856244B (zh) * | 2021-10-21 | 2023-03-21 | 国网浙江省电力有限公司检修分公司 | 一种具有梯度结构的多孔复合材料及其制备方法和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004158A1 (en) * | 1993-07-29 | 1995-02-09 | The Upjohn Company | Use of heparanase to identify and isolate anti-heparanase compound |
US20050169907A1 (en) * | 2004-01-22 | 2005-08-04 | Hadasit Medical Research Service And Development Company Ltd. | Substances directed against a specific sequence essential for heparanase catalytic activity and uses thereof as heparanase inhibitors |
WO2007013050A1 (en) * | 2005-07-25 | 2007-02-01 | Hadasit Medical Research Services & Development Ltd. | Heparanase-derived peptide dimers and their uses as inhibitors of heparanase |
CN101885787A (zh) * | 2009-05-11 | 2010-11-17 | 深圳市海普瑞药业股份有限公司 | 一种从肝素副产物纯化硫酸乙酰肝素的方法 |
CN103288981A (zh) * | 2013-06-20 | 2013-09-11 | 深圳市海普瑞药业股份有限公司 | 一种抑制细胞增殖的硫酸酯化的硫酸乙酰肝素 |
CN103739743A (zh) * | 2008-09-11 | 2014-04-23 | 新加坡科技研究局 | 糖胺聚糖的分离和鉴定 |
CN105504097A (zh) * | 2015-12-30 | 2016-04-20 | 深圳市海普瑞药业股份有限公司 | 一种硫酸化肝素寡糖及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL175571A0 (en) * | 2006-05-11 | 2008-01-20 | Ben Zion Katz | Use of non-catalytic form of heparanase and peptides thereof for reverising the anti-coagulant effects of heparinoids |
CN102796723A (zh) * | 2012-09-11 | 2012-11-28 | 深圳市海普瑞药业股份有限公司 | 肝素酶i的固定化方法 |
-
2019
- 2019-12-27 WO PCT/CN2019/129112 patent/WO2021128255A1/zh active Application Filing
- 2019-12-27 CN CN201980103155.9A patent/CN114846137B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004158A1 (en) * | 1993-07-29 | 1995-02-09 | The Upjohn Company | Use of heparanase to identify and isolate anti-heparanase compound |
US20050169907A1 (en) * | 2004-01-22 | 2005-08-04 | Hadasit Medical Research Service And Development Company Ltd. | Substances directed against a specific sequence essential for heparanase catalytic activity and uses thereof as heparanase inhibitors |
WO2007013050A1 (en) * | 2005-07-25 | 2007-02-01 | Hadasit Medical Research Services & Development Ltd. | Heparanase-derived peptide dimers and their uses as inhibitors of heparanase |
CN103739743A (zh) * | 2008-09-11 | 2014-04-23 | 新加坡科技研究局 | 糖胺聚糖的分离和鉴定 |
CN101885787A (zh) * | 2009-05-11 | 2010-11-17 | 深圳市海普瑞药业股份有限公司 | 一种从肝素副产物纯化硫酸乙酰肝素的方法 |
CN103288981A (zh) * | 2013-06-20 | 2013-09-11 | 深圳市海普瑞药业股份有限公司 | 一种抑制细胞增殖的硫酸酯化的硫酸乙酰肝素 |
CN105504097A (zh) * | 2015-12-30 | 2016-04-20 | 深圳市海普瑞药业股份有限公司 | 一种硫酸化肝素寡糖及其制备方法和应用 |
Non-Patent Citations (5)
Title |
---|
HOWARD BERNSTEIN ET AL.: "An Investigation of Heparinase Immobilization", 《APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY》, vol. 16, pages 131 - 133 * |
HUAJUN ZHAO ET AL.: "Oligomannurarate Sulfate, a Novel Heparanase Inhibitor Simultaneously Targeting Basic Fibroblast Growth Factor, Combats Tumor Angiogenesis and Metastasis", 《CANCER RESEARCH》 * |
STEVEN C. MARCH ET AL.: "A Simplified Method for Cyanogen Bromide Activation of Agarose for Affinity Chromatography", 《ANALYTICAL BIOCHEMISTRY》, pages 149 - 150 * |
于广利等: "《糖药物学》", 31 October 2012, 中国海洋大学出版社, pages: 324 - 325 * |
何明生等: "《现代肿瘤临床实用治疗学》", 31 October 2004, 云南科学技术出版社, pages: 120 * |
Also Published As
Publication number | Publication date |
---|---|
CN114846137B (zh) | 2024-06-28 |
WO2021128255A1 (zh) | 2021-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Habuchi et al. | Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor | |
AU654804B2 (en) | Wound healing preparations containing heparanase | |
US5039529A (en) | Novel heparin derivatives | |
HUT59828A (en) | Process for producing oligosaccharid-containing inhibitors of endothelial celle-multiplication and inhibitors of angiogenezis | |
Fan et al. | Relationship of the inhibition of cell migration with the structure of ginseng pectic polysaccharides | |
CN1543351A (zh) | 用于提高癌症治疗疗效的方法 | |
Ruggiero et al. | Is chondroitin sulfate responsible for the biological effects attributed to the GC protein-derived Macrophage Activating Factor (GcMAF)? | |
US7005426B2 (en) | Folic acid-polysaccharide complex, its preparation method and pharmaceutical composition containing the same as active component | |
Blackhall et al. | Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates | |
CA2361612A1 (en) | Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans | |
Coltrini et al. | Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor | |
WO1993005167A1 (en) | Cell-type specific heparan sulfate proteoglycans and their uses | |
US20190002596A1 (en) | Sulfated heparin oligosaccharide and preparation method and application thereof | |
CN114846137A (zh) | 一种亲和填料及其制备方法和应用 | |
AU2018202402B2 (en) | Homogeneous polysaccharide with immunoregulation activity and preparation method thereof | |
Bertolesi et al. | Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins | |
CN114957432B (zh) | 一种能特异性识别肝素类结构的蛋白探针var2hp及其编码基因与应用 | |
Poggi et al. | Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide | |
CN118684788A (zh) | 一种亲和填料及其制备方法和应用 | |
WO2019205256A1 (zh) | 一种硫酸化肝素二糖接枝聚甲基丙烯酰乙醇胺及其制备方法 | |
JPH02191601A (ja) | 合成コンドロイチン硫酸プロテオグリカンを含有する組織癒着防止剤 | |
JP3390836B2 (ja) | 線維芽細胞増殖因子に結合性を有するオリゴ糖及びその製造法 | |
Nagasaki et al. | Heparin potentiates the action of plasma membrane‐associated growth stimulatory activity | |
EP0751958B1 (en) | Flucose containing proteoglycan or acid glycan and their pharmaceutical use | |
CN114901702B (zh) | 一种糖胺聚糖衍生物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |